ANDA 76284, held by ANI Pharmaceuticals. Tizanidine Hydrochloride.
As of Nov 20, 2026, ANDA 76284 (Tizanidine Hydrochloride), held by ANI Pharmaceuticals, was first approved by FDA on Jul 3, 2002, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 3, 2002 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Discontinued |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Discontinued |
| Nov 18, 2002 | Supplement 2Labeling | Approved | None posted |
| Jul 3, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters